Business
Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta
Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nValeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta\nCanada NewsWire\nMONTREAL, Nov. 3, 2021\n\n\n\nFirst provincial public listing secured for both asthma medications Additional provincial public reimbursement coverage expected to follow soon85% private payer health plan coverage across Canada MONTREAL, Nov. 3, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement (\"PLA\") with Alberta Minister of Health, for the listing and public reimbursement of Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapies, on the Alberta Drug Benefit list effective November 1, 2021. \n\n \n \n \n \n \n \n\n \n\"Expanding access and reimbursement for Enerzair and Atectura throughout Canada is a key milestone for our respiratory program. We are pleased to report today the first provincial public coverage for both drugs following the recent successful completion of our negotiations with pCPA\", said Frederic Fasano, Valeo's President and Chief Operating Officer. \"Enerzair and Atectura are both valuable additions to the Canadian asthma treatment landscape and we are looking forward to working with all remaining jurisdictions across the country to ensure broad patient access\". \nAs previously disclosed, Enerzair and Atectura are also currently listed for reimbursement under private payer health plans which represent all together 85% of privately covered lives accross Canada. \nAbout Enerzair® Breezhaler®      \nEnerzair® Breezhaler® is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or...